H1N1 vaccination in Sjögren's syndrome triggers polyclonal B cell activation and promotes autoantibody production
Open Access
- 1 October 2017
- journal article
- research article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 76 (10) , 1755-1763
Abstract
Objectives Vaccination of patients with rheumatic disease has been reported to result in lower antibody titres than in healthy individuals. However, studies primarily include patients on immunosuppressive therapy. Here, we investigated the immune response of treatment-naïve patients diagnosed with primary Sjögren’s syndrome (pSS) to an H1N1 influenza vaccine. Methods Patients with Sjögren’s syndrome without immunomodulatory treatment and age-matched and gender-matched healthy controls were immunised with an H1N1 influenza vaccine and monitored for serological and cellular immune responses. Clinical symptoms were monitored with a standardised form. IgG class switch and plasma cell differentiation were induced in vitro in purified naïve B cells of untreated and hydroxychloroquine-treated patients and healthy controls. Gene expression was assessed by NanoString technology. Results Surprisingly, treatment-naïve patients with Sjögren’s syndrome developed higher H1N1 IgG titres of greater avidity than healthy controls on vaccination. Notably, off-target B cells were also triggered resulting in increased anti-EBV and autoantibody titres. Endosomal toll-like receptor activation of naïve B cells in vitro revealed a greater propensity of patient-derived cells to differentiate into plasmablasts and higher production of class switched IgG. The amplified plasma cell differentiation and class switch could be induced in cells from healthy donors by preincubation with type 1 interferon, but was abolished in hydroxychloroquine-treated patients and after in vitro exposure of naïve B cells to chloroquine. Conclusions This comprehensive analysis of the immune response in autoimmune patients to exogenous stimulation identifies a mechanistic basis for the B cell hyperactivity in Sjögren’s syndrome, and suggests that caution is warranted when considering vaccination in non-treated autoimmune patients.Keywords
Funding Information
- Vetenskapsrådet
- Stiftelsen Konung Gustaf V:s 80-Ã¥rsfond
- Karolinska Institutet
- Stockholms Läns Landsting
- Hjärt-Lungfonden
- Reumatikerförbundet
This publication has 48 references indexed in Scilit:
- Immunopathogenic mechanisms of systemic autoimmune diseaseThe Lancet, 2013
- TLR7 Recognition Is Dispensable for Influenza Virus A Infection but Important for the Induction of Hemagglutinin-Specific Antibodies in Response to the 2009 Pandemic Split Vaccine in MiceJournal of Virology, 2012
- Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosusArthritis Research & Therapy, 2012
- Protective effect of A/H1N1 vaccination in immune-mediated disease--a prospectively controlled vaccination studyRheumatology, 2011
- The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD88Nature Immunology, 2010
- EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndromeAnnals of the Rheumatic Diseases, 2010
- Loss of the lupus autoantigen Ro52/Trim21 induces tissue inflammation and systemic autoimmunity by disregulating the IL-23–Th17 pathwayJournal of Experimental Medicine, 2009
- Emergence of a Novel Swine-Origin Influenza A (H1N1) Virus in HumansNew England Journal of Medicine, 2009
- Peripheral blood gene expression profiling in Sjögren's syndromeGenes & Immunity, 2009
- RETRACTED ARTICLE: DCs induce CD40-independent immunoglobulin class switching through BLyS and APRILNature Immunology, 2002